Category Archives: "Partners"

Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis [...]
Genzyme introduces “vs.MS”, a global initiative
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Bayer receives FDA approval for BETACONNECT
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Multiple Sclerosis Coalition applauds passage of 21st Century Cures Act
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Genentech’s Ocrelizumab reduced both relapses and disability progression versus Rebif
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition announces new board President
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa, the first generic competitor to Copaxone 20mg
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM